Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2018-08-03 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
独立董事关于关联交易的事前认可
Board/Management Information Classification · 95% confidence The document is a statement from independent directors regarding prior approval of a related party transaction, referencing compliance with stock exchange listing rules and corporate governance guidelines. It is a formal announcement about board-level approval of a specific transaction, not a full report or financial statement. The content focuses on board/management information related to governance and transaction approval. The document length is short and does not contain financial data or detailed report content. Therefore, it fits best under Board/Management Information (MANG).
2018-08-03 Chinese
第八届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding a specific contract approval. It includes details about the board meeting, attendance, and voting results. There is no financial data, no mention of annual or quarterly reports, no audit information, and no regulatory certifications. The document is an announcement of a board meeting decision, which fits the category of Board/Management Information (MANG). The document length is short and focused on management decisions rather than financial or regulatory filings.
2018-08-03 Chinese
关联交易公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a related party transaction between the company and its controlling shareholder's affiliated entity. It details the transaction overview, parties involved, pricing policy, contract terms, payment methods, and independent directors' opinions. There are no financial statements or comprehensive financial data presented. The document is a formal disclosure of a related party transaction as required by stock exchange rules, not a full financial report or earnings release. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory announcement about a specific transaction. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is short (2388 characters), and it is not a report publication announcement or certification letter, so RNS fits best.
2018-08-03 Chinese
独立董事意见
Regulatory Filings Classification · 90% confidence The document is a statement of independent directors' opinions regarding a transaction, referencing compliance with governance guidelines and company bylaws. It does not contain financial statements or detailed financial data. The content is related to governance and board oversight but is not an announcement of board changes, nor a full management report. It is a regulatory compliance statement related to governance practices, fitting best under Regulatory Filings (RNS) as it does not meet criteria for other specific categories.
2018-08-03 Chinese
关于公司网站启用新域名的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement about the company's website domain name change. It contains no financial data, no report content, no voting results, no management changes, and no regulatory certifications. It is a general regulatory announcement informing investors about a non-financial operational update. The document length is only 380 characters, indicating it is a brief notice rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2018-07-27 Chinese
2018年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the half-year period ending June 30, 2018, indicating expected net profit and earnings per share with a comparison to the previous year. It explicitly states that the forecast is unaudited and that the final data will be in the 2018 half-year report. The document is short (697 characters) and serves as a preliminary earnings forecast rather than a full interim report containing actual financial statements or detailed analysis. Therefore, it fits the category of an Earnings Release (ER), which is an initial announcement of periodic financial results highlighting key figures and expectations. H1 2018
2018-07-13 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.